Enovis Corp

Oliver Engert, Chief Administrative Officer of Enovis Corporation, purchased 7,598 shares of common stock in transactions on Sept. 2, 2026, and Sept. 3, 2026, according to a recent SEC Form 4 filing. The purchase was executed at a weighted average price of $19.74 per share, for a total transaction value of roughly $150,000, with the shares acquired in multiple transactions at price ranges of $19.33 to $19.75 and $20.145 to $20.50. The addition brings Engert's total direct holding to 61,238 shares, a stake of 0.11% in the $1.1 billion medical technology enterprise, worth about $1.19 million based on the Sept. 3, 2026 market close of $19.40. Enovis reported trailing twelve-month revenue of $2.3 billion and a net loss of $1.1 billion, while net debt stands at $1.36 billion. The stock closed at $18.56 on Sept. 4, 2026.

Enovis has entered a binding offer to acquire eCential Robotics, a developer of surgical robotics technology, for an enterprise value of €155 million, with up to €35 million in milestone payments. The deal, expected to close by the end of 2026, will be funded with cash and revolving-credit capacity, and it expands Enovis' ASTRA ecosystem into robotics. The company plans to launch a next-generation robotic platform for total knee procedures within two years, followed by a shoulder application, with initial commercial contributions expected in 2028. Enovis expects the acquisition to temporarily dilute adjusted EBITDA margins by roughly 100 basis points in 2027, while leverage rises by about half a turn, but it still targets at least $100 million in free cash flow next year.

Enovis reaffirmed its 2026 guidance during its second-quarter earnings call, targeting free cash flow conversion of greater than 25%. CEO Damien McDonald reported organic growth of 5%, driven by 6% organic growth in Recon and 3% in P&R, with U.S. Recon led by 8% organic growth in Hips and Knees. CFO Phillip Berry noted second-quarter sales of $583 million, adjusted gross margin of 62%, adjusted EBITDA margin of 17.9%, and adjusted earnings per share of $0.90. The company expects a seasonally softer third quarter followed by sales acceleration in the fourth quarter, supported by the full commercial launch of the Arvis system in the U.S. and continued adoption of the Nebula platform.

Several stocks made notable moves this week. HCA Healthcare fell 6.7% on Tuesday after releasing preliminary second-quarter results and cutting its full-year 2026 profit guidance. UnitedHealth rose 5.1% on Thursday after reporting second-quarter earnings that surpassed Wall Street expectations, driven by improved profitability. CrowdStrike gained 9.8% on Tuesday after U.S. and international security agencies issued a joint warning about Russian state-sponsored cyber threats targeting critical infrastructure. RXO rose 4.2% on Monday after Stifel raised its price target on the stock to $30 from $22 while maintaining a Buy rating. Enovis rose 3.6% on Monday after announcing the U.S. launch of CT-RevitL, a new veterinary laser therapy system from its Companion Animal Health business.

Innovative Eyewear shares surged 63% after the company reported preliminary second-quarter net sales of approximately $0.99 million, a 71% year-over-year increase, and announced new retail partnerships in Canada and the United States. The company received an initial purchase order from a Canadian optical retail group with 345 locations and was awarded a 50-store test with a major U.S. retailer, both expected to begin in the third quarter of 2026. Separately, Seer jumped 35% after its Chair and CEO proposed to acquire all outstanding Class A shares for $2.45 per share in cash plus two contingent value rights, with the board forming a special committee to evaluate the offer. Orthofix and Enovis rallied over 15% each after CMS withdrew reimbursement changes for non-invasive bone growth stimulators, restoring Medicare rates to pre-May 2026 levels. Other notable movers included YD Bio, up 23% on no specific news, and Adlai Nortye, which gained 15% amid progress updates on its cancer therapy pipeline.

Shares of Enovis Corporation jumped 15% after the Centers for Medicare & Medicaid Services reversed previously announced reimbursement cuts for the company's non-invasive bone growth stimulators. The decision marks a significant rebound for the stock, which had declined 12% during a prior session. The positive move was also supported by broader strength in the healthcare sector, which was the top-performing sector in the S&P 500 after a soft June jobs report dampened expectations for interest rate hikes.

Enovis, Insteel Industries, Mueller Water Products, and Proto Labs are highlighted as growth stocks trading under $100 with strong long-term potential. Enovis saw 11% reconstructive sales growth in Q1 2026 and holds a Strong Buy consensus with a $42 average price target, roughly 91% above its current $22. Insteel Industries reported Q2 sales up 7.5% year over year, driven by infrastructure spending and record data center construction permits. Mueller Water Products posted Q2 net sales up 4.6% and benefits from $55 billion in federal water infrastructure funding. Proto Labs is pivoting from prototyping to production-grade manufacturing, with a $1.2 billion market cap and shares at $80.